EuroBiotech: More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> Vernalis paid £10 million ($13 million) to terminate its agreement with Tris Pharma. The decision follows regulatory setbacks for products covered by the agreement. Release (PDF)

> Syncona founded two gene therapy startups. The British life science investor committed $23 million to SwanBio and $12 million to Orbit Biomedical. Statement (PDF)

> Newron Pharmaceuticals delayed a readout from its phase 3 Rett syndrome clinical trial by up to six months. Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> PharmaMar asked to change the primary endpoint of its phase 3 lung cancer trial. Moving from progression-free to overall survival will delay the readout until the second half of next year. Release (PDF)

> Motif Bio completed the rolling NDA for its antibiotic iclaprim. Statement

Suggested Articles

Acceleron’s sotatercept outdid placebo at reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

China’s Biotheus picked up the rights to Tilt Biotherapeutics’ lead oncolytic virus program in greater China.

A Cedars-Sinai team used stem cells to uncover a key mechanism of young onset Parkinson's, as well as a potential remedy—an existing skin treatment.